Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

Hepatology

Volumn 44, Issue 4, 2006, Pages 896-906

  Doyle, Sean E ^a   Schreckhise, Heidi ^a   Khuu Duong, Kien ^a   Henderson, Katherine ^a   Rosler, Robert ^a   Storey, Harold ^a   Yao, Lena ^a   Liu, Hong ^a   Barahmand Pour, Fariba ^a   Sivakumar, Pallavur ^a   Chan, Chung ^a   Birks, Carl ^a   Foster, Don ^a   Clegg, Christopher H ^a   Wietzke Braun, Perdita ^b   Mihm, Sabine ^b   Klucher, Kevin M ^a  

^a ZYMOGENETICS INC   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2'5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; INTERLEUKIN 28 ALPHA RECEPTOR; INTERLEUKIN 29; INTERLEUKIN 29 RECEPTOR; INTERLEUKIN RECEPTOR; PEGINTERFERON ALPHA2A; PEGYLATED INTERLEUKIN 29; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SYNTHETASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYTOKINE; INTERLEUKIN 29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TYPE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MICROARRAY ANALYSIS; MX1 GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VIRUS LOAD; VIRUS REPLICATION; WEST NILE FLAVIVIRUS; ANIMAL; CELL LINE; CHO CELL; CRICETULUS; DNA MICROARRAY; DRUG EFFECT; FLAVIVIRUS; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; METABOLISM; PHOSPHORYLATION; VIROLOGY; VIRUS HEPATITIS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINES; FLAVIVIRUS; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS, VIRAL, HUMAN; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN; RNA; STAT1 TRANSCRIPTION FACTOR; VIRAL LOAD; VIRUS REPLICATION;

EID: 33750631014     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21312     Document Type: Article

References (47)

1. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.
2. Vilcek J, .Sen GC. Interferons and other cytokines. In: Fields BN, Knipe DM, Howley PM, eds. Fundamental Virology. 3rd edition. New York: Lippincott-Raven Publishers, 1996:341-365.
3. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-390.
4. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-68.
5. Kotenko SV, Gallagher G, Baurin W, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
6. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004;76:314-321.
7. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-1683.
8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
9. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24(Suppl 1):45-53.
10. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
11. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med 2004;71 (Suppl 3):S8-S12.
12. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
13. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
14. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
15. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. HEPATOLOGY 1997;26(Suppl):112S-121S.
16. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004;84:1148-1159.
17. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. HEPATOLOGY 1997;25:735-739.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
19. Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewcz M, Yao L, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006;117:418-425.
20. Fu L, Cheng YC. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother 2000;44:3402-3407.
21. Buckwold VE, Wilson RJ, Nalca A, Beer BB, Voss TG, Turpin JA, et al. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res 2004;61:57-62.
22. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-1974.
23. Ross RS, Viazov S, Sarr S, Hoffmann S, Kramer A, Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods 2002;101:159-168.
24. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002;55:107-116.
25. Sansonno D, Iacobelli AR, Cornacchiulo V, Distasi M, Dammacco F. Immunohistochemical detection of hepatitis C virus-related proteins in liver tissue. Clin Exp Rheumatol 1995;13(Suppl 13):S29-S32.
26. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBc positive carriers of hepatitis B virus. HEPATOLOGY 1983;3:656-662.
27. Korba BE, Gerin JL. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 1992;19:55-70.
28. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol 1992;28A:136-142.
29. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis 1997;176:1209-1214.
30. Morsica G, Tambussi G, Sitia G, Novati R, Lazzarin A, Lopalco L, et al. Replication of hepatitis C virus in B lymphocytes (CD19+). Blood 1999; 94:1138-1139.
31. Vallat L, Benhamou Y, Gutierrez M, Ghillani P, Hercher C, Thibault V, et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004;50:3668-3678.
32. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
33. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14: 778-809.
34. Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O, Caput D, et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem 1995;270:23860-23866.
35. Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U. Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines. Cell Mol Life Sci 2003;60:1235-1248.
36. Fiorucci G, Vannucchi S, Chiantore MV, Percario ZA, Affabris E, Romeo G. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential. Curr Pharm Des 2005; 11:933-944.
37. Bluyssen AR, Durbin JE, Levy DE. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev 1996;7:11-17.
38. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000;19:2638-2644.
39. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
40. Helfman DM, Kim EJ, Lukanidin E, Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005;92:1955-1958.
41. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 2002;42:65-78.
42. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004;82:508-515.
43. Nagata T, Takahashi Y, Ishii Y, Asai S, Nishida Y, Murata A, et al. Transcriptional profiling in hepatoblastomas using high-density oligonucleotide DNA array. Cancer Genet Cytogenet 2003;145:152-160.
44. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
45. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851-3854.
46. Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 2003;44:1113-1120.
47. Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S, Chen Z, et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A 2001;98:9511-9516.